Halozyme Therapeutics HALO Insider Ownership

Updated Oct 9, 2026

Over the past year, HALO insiders sold $48.38 million of stock (584.47K shares) on the open market and bought none.

• By number of insiders, Halozyme Therapeutics saw 5 insiders sell on the open market over the past 12 months and none buy.
• Helen Torley (President and CEO) was the top open-market seller of Halozyme Therapeutics over the past 12 months, with $42.15 million sold (508.49K shares) and the latest sale on October 8, 2026.
• Apart from open-market trades, HALO insiders received 10.59K shares in stock awards, acquired 759.84K shares through option exercises and conversions, gave up 114.82K shares to cover taxes or exercise prices and gave away 25K shares as gifts in the past 12 months.
• Per Business Quant, HALO insiders together hold 1.44Mn shares based on their latest Form 4 filings, or 1.23% of the 117.27Mn shares outstanding; that total is down 0.48% from 1.45Mn shares at the end of Q2 2026 and up 6.72% from 1.35Mn shares at the end of Q3 2025.
• By type of ownership, HALO insiders hold all of their 1.44Mn shares directly.
• Per Business Quant, 15 insiders of HALO hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Halozyme Therapeutics' top three insider holders by shares held are Helen Torley (President and CEO, 767.78K shares), Connie Matsui (Director, 183.03K shares) and Michael J. Labarre (SVP, Chief Technical Officer, 173.76K shares).
• Helen Torley alone accounts for 53.19% of the shares held by Halozyme Therapeutics insiders.
• A total of 50 Form 4 filings with transactions in Halozyme Therapeutics stock were made over the past 12 months, by 14 insiders.
• Insider figures for HALO include Form 4 filings through October 8, 2026.